Skip to main content
OpenTrials
Completed

NCT Number: NCT02224768

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution, St Ives, Cambridgeshire, United Kingdom

Loading trial locations.

About this study

A total sample size of 160 to 200 HCPs and 160 to 200 patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

  • HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose

Treatment and study plan

Ipilimumab

Drug

Primary outcomes

  1. The proportion of YERVOY HCPs that are aware of the existence of the risk communications tools and how the tools were accessed (i.e. paper or electronic versions)

    Time frame: 6 months

    Distribution metrics and awareness of the tools from responses through the survey will be analysed and descriptive statistics will be used within the different participant groups

  2. Questionnaire: "Who uses the RM communication tools, how, when they are used and how often they are used"

    Time frame: 6 months

    Web downloads metrics will be collected and the usage of tools from responses in the survey will be analysed, and descriptive statistics will be used within the participant groups

  3. Level of knowledge and comprehension of the key elements of important identified risks associated with YERVOY treatment based on the scores obtained from the Questionnaire Surveys

    Time frame: 6 months

    Knowledge and comprehension in HCPs and patients, the knowledge surveys will provide the following data

    • Total number of responses to the question including the proportions of correct answers to questions where appropriate
    • Number or frequency and proportion of response options selected
    • Percentage of responses/total responses per option
    • Mean value and standard deviation (for appropriate questions)

    From the obtained data, Acceptable levels of correct responses will be determined, post data analysis, reporting and discussion with EMA, to set baseline levels for potential future evaluations and then the scores will be assessed

  4. HCP and patient behaviours via behavioural questions and scenarios based on the scores obtained from the Questionnaire Surveys

    Time frame: 6 months

    For determining appropriate behaviours in HCPs and patients, ideal expected behaviours will be mapped to the ideal care pathway from the Failure Modes and Effects Analysis (FMEA) as described in the RMP. The metrics will show:

    • Total of number of participants answering the question.
    • Proportions of participants providing correct answers (to identify knowledge and comprehension)
    • Proportion of participants showing expected (ideal) behaviour - i.e. correct answers to individual questions.
    • Proportion of participants showing non-ideal behaviour - i.e. partially correct or incorrect answers to individual questions.

    Analysis will examine knowledge, comprehension and behaviours for different participant types (HCP, Hospital type and Country)

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

YERVOY Risk Minimisation Tool Evaluation Survey

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Aug 25, 2014
Registry last updated
Dec 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.